Sign in
BYSI Stock Price, Chart, Stats & News
BeyondSpring Inc.
Save
65.17M
Market cap
–
Current P/E
10.54x
Forward P/E
BYSI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 1.04% |
ROA | -30.82% |
ROE | 26.10% |
D/E | -0.01x |
Interest coverage ratio | – |
BYSI valuation
P/E | – |
P/S | – |
P/B | -2.01x |
P/CF | -3.21x |
P/FCF | -3.25x |
P/OCF | -3.21x |
PEG | 0.05x |
EV multiple | -8.43x |
About
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer.
Similar securities
Based on sector and market capitalization
Report issue